Feasibility, safety and cost-effectiveness of transjugular liver biopsy following major surgery in patients with haemophilia.
Prior to the introduction of virally inactivated clotting factor concentrates, the majority of patients with haemophilia became infected with the hepatitis C virus. Although transjugular liver biopsy can be safely performed in these patients, the procedure is associated with a significant financial burden mainly related to replacement therapy with clotting factor. The purpose of this study was to evaluate the feasibility and safety of transjugular liver biopsy in patients with haemophilia substituted with clotting factor concentrates for major surgical procedures. Over the last 5 years, transjugular liver biopsy was performed in nine patients with haemophilia within 1-10 days after orthopaedic (7), thoracic (1) or abdominal surgery (1). All patients had abnormal liver function tests and persistent hepatitis C viraemia. At the time of the biopsy, patients received recombinant factor VIII delivered by dose-adjusted continuous infusion through a central catheter inserted preoperatively in the left internal jugular (n = 8) or in an ante-cubital vein (n = 1). Before the biopsy, basal FVIII levels were raised to 80-100% by a bolus infusion and maintained above 80% for 24 h. The biopsy was informative in all cases. Only one patient developed an episode of supraventricular dysrhythmia. No bleeding or infectious complications were observed. When compared with elective liver biopsy performed outside the postsurgical period, the cost-savings per biopsy were 19 875 +/- 2660 euro. This study shows that intensive replacement therapy required by surgical procedures provides a safe and cost-effective opportunity for transjugular liver biopsy in patients with haemophilia and active hepatitis C.
Detrait
M
M
Haemostasis and Thrombosis Unit, Division of Haematology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Avenue Hippocrate 10, 1200 Brussels, Belgium.
Pothen
D
D
Brenard
R
R
Starkel
P
P
Hermans
C
C
D000328:Adult; D001706:Biopsy / Q000191:economics / Q000379:methods; D003365:Costs and Cost Analysis; D005240:Feasibility Studies; D005260:Female; D006467:Hemophilia A / Q000150:complications / Q000191:economics / Q000821:virology*; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000191:economics; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007601:Jugular Veins; D008099:Liver / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome